ISA Pharmaceuticals selects product candidate for clinical trial with first in class COVID-19 immunotherapy

First Patient Treated in Phase II Combination Trial of ISA Pharmaceuticals’ Lead Immunotherapy ISA101b with Keytruda®

ISA106 – SLP therapeutic for COVID-19

ISA Pharmaceuticals to present at the Virtual 6th Solebury Trout Summer 2020 Private Company Showcase

ISA Pharmaceuticals to present at the 33rd International Papillomavirus Conference & Basic Science

ISA Pharmaceuticals will move to BioPartner 5

ISA Pharmaceuticals receives US Orphan-Drug Designation for ISA101b in HPV16-positive Cervical Cancer

ISA Pharmaceuticals Strengthens Strategic Immuno-Oncology Collaboration with Regeneron

Vaccine-Chemo Combo Shows Promise in Treating Advanced, HPV-Associated Cervical Cancer